Academic Journal
Regulatory ambiguity and governance challenges for psilocybin mushrooms in Brazil.
| Τίτλος: | Regulatory ambiguity and governance challenges for psilocybin mushrooms in Brazil. |
|---|---|
| Συγγραφείς: | Nogueira M; Scientific Department, Instituto Micélio Sagrado, São Paulo, Brazil. Electronic address: marcelnogueira7@gmail.com., García-Hernández S; Scientific Department, Instituto Micélio Sagrado, São Paulo, Brazil; Department of Ecology, Biosciences Institute, University of São Paulo, São Paulo, Brazil., Roberto GS; Scientific Department, Instituto Micélio Sagrado, São Paulo, Brazil; Department of Clinical and Toxicological Analyses, School of Pharmaceutical Sciences, University of São Paulo, São Paulo, Brazil., Rodrigues DC; Scientific Department, Instituto Micélio Sagrado, São Paulo, Brazil. |
| Πηγή: | The International journal on drug policy [Int J Drug Policy] 2026 Apr; Vol. 150, pp. 105198. Date of Electronic Publication: 2026 Feb 18. |
| Τύπος έκδοσης: | Journal Article |
| Γλώσσα: | English |
| Στοιχεία περιοδικού: | Publisher: Elsevier Country of Publication: Netherlands NLM ID: 9014759 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1873-4758 (Electronic) Linking ISSN: 09553959 NLM ISO Abbreviation: Int J Drug Policy Subsets: MEDLINE |
| Imprint Name(s): | Publication: 1998- : Amsterdam ; New York : Elsevier Original Publication: Liverpool, England : International Journal on Drug Policy |
| Ιατρικοί όροι (MeSH): | Drug and Narcotic Control*/legislation & jurisprudence , Psilocybin* , Hallucinogens* , Legislation, Drug*, Public Health/legislation & jurisprudence ; Psilocybe/chemistry ; Brazil ; Humans ; Government Regulation |
| Περίληψη: | The legal status of psilocybin mushrooms in Brazil remains ambiguous, despite increasing global scientific and public interest in their therapeutic and ceremonial use. This commentary examines the regulatory uncertainty surrounding psilocybin mushrooms in Brazil and situates the debate within broader legal, drug policy, public health, and Indigenous rights discussions. Building on academic literature, media reports, jurisprudence, and insights drawn from the regulatory experience surrounding ayahuasca, our commentary argues that any future coherent approach to psilocybin regulation would need to integrate scientific evidence, Indigenous knowledge, and ethical governance. We underscore the importance of regulatory mechanisms that ensure Indigenous leadership in decision-making and protect traditional knowledge, consistent with international frameworks such as the World Health Organization's Global Traditional Medicine Strategy and the United Nations Declaration on the Rights of Indigenous Peoples. Despite the growing international momentum toward psychedelic reform, the absence of a coherent framework in Brazil continues to generate legal uncertainty and arbitrary enforcement. Accordingly, our reflection points to the need to open formal deliberative spaces by regulatory bodies, particularly the Brazilian Health Regulatory Agency (ANVISA) and the National Drug Policy Council (CONAD), to develop evidence-based, culturally sensitive, and constitutionally consistent policies for psilocybin regulation in Brazil. (Copyright © 2026 Elsevier B.V. All rights reserved.) |
| Competing Interests: | Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. |
| Contributed Indexing: | Keywords: ANVISA; CONAD; Drug policy; Psilocybe cubensis; Psilocybin; Psychedelics |
| Substance Nomenclature: | 2RV7212BP0 (Psilocybin) 0 (Hallucinogens) |
| Entry Date(s): | Date Created: 20260219 Date Completed: 20260708 Latest Revision: 20260708 |
| Update Code: | 20260708 |
| DOI: | 10.1016/j.drugpo.2026.105198 |
| PMID: | 41713116 |
| Βάση Δεδομένων: | MEDLINE |
| ISSN: | 1873-4758 |
|---|---|
| DOI: | 10.1016/j.drugpo.2026.105198 |